Calyxo has raised $40m in a financing round; at the same time, the company has achieved a milestone of 40,000 kidney stone removal procedures completed with its central venous access catheter (CVAC) system.
The Series F financing round was led by Ally Bridge Group and Janus Henderson Investors, with continued support from Questa Capital, Avidity Partners, and CRG.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Calyxo’s CVAC system provides continuous aspiration of stone fragments during and after laser lithotripsy to support more complete kidney stone clearance. The system obtained US Food and Drug Administration (FDA) clearance in March 2024.
Calyxo plans to apply the latest funds towards clinical and health economic evidence generation through ongoing and future studies to evaluate the system’s long-term outcomes and downstream healthcare utilisation, along with making expansions to its commercial infrastructure.
Past research of Calyxo’s CVAC has found that 95% of patients experienced no adverse events (AEs) following its use alongside steerable ureteroscopic renal evacuation (SURE) for kidney stone clearance, versus 83.5% who received standard ureteroscopy.
Coinciding with the latest financing round, Calyxo shared that it has recently completed 40,000 kidney stone removal procedures using its CVAC system.
Calyxo CEO, Joe Catanese, commented: “Real-world experience, together with an established body of clinical evidence, indicates that the CVAC system is moving beyond early adoption and becoming an important part of the standard of care in kidney stone treatment. This financing allows us to move faster in advancing our technology and expanding the evidence base to further improve patient care.”
According to the American Urological Association (AUA), approximately 10% of people in the US will have a kidney stone at some point in their lives. In the broader kidney care space, funding is an ongoing challenge. An American Society of Nephrology (ASN) report from November 2025 highlights that the US funding imbalance in kidney care has stalled progress, leaving dialysis as the default therapy for kidney failure, despite its “debilitating impact” and poor survival outcomes.
To turn the tide on poor survival outcomes for conditions such as end-stage kidney disease (ESKD), advocates are growing more vocal about shifting the focus to kidney care, and have urged the World Health Organization (WHO) to classify kidney disease as a non-communicable disease priority globally.
